Search research articles
Contact Us
Filters
Showing results (81-90 of 172) with videos related to
Page
of 18
Sort By:
The Journal of Experimental Medicine
|
November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The American Journal of Surgical Pathology
|
August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern
Genevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Cell
|
December 2, 2017
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J Topper, Michelle Vaz, Katherine B Chiappinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C Osorio, Kathryn C Arbour, Dung T Le, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 172) with videos related to
Sort By:
Page
of 18
The Journal of Experimental Medicine
|
November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The American Journal of Surgical Pathology
|
August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern
Genevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Cell
|
December 2, 2017
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J Topper, Michelle Vaz, Katherine B Chiappinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C Osorio, Kathryn C Arbour, Dung T Le, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
Page
of 18